IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation , a global leader in medical technologies to treat advanced cardiovascular disease, is scheduled to participate in the Merrill Lynch 2006 Global Drug, Device and Biotechnology Conference at the Grand Hyatt Hotel in New York on February 7, 2006.
Michael A. Mussallem, Edwards Lifesciences' chairman and CEO, will speak to the attendees of the conference that day at 4:00 p.m. EST. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, Fogarty, LifeStent, PERIMOUNT and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the U.S. Patent and Trademark Office.
Edwards Lifesciences CorporationCONTACT: Investors, David K. Erickson, +1-949-250-6826, or Media, Barry R.Liden, +1-949-250-5070, both of Edwards Lifesciences Corporation
